APR 19 2004 Sur

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no pessons are required to respond to a collection of information unless it displays a valid OMB control number.

#### **Application Number** 10/728,665 **TRANSMITTAL** Filing Date December 5, 2003 First Named Inventor **FORM** Satyanarayana MEDICHERLA Art Unit 1614 (to be used for all correspondence after initial filing) **Examiner Name** Not Yet Assigned Attorney Docket Number 12+79 Total Number of Pages in This Submission 219002032800 Refs

. EN	CLOSURES (Check all that app	oly)				
Fee Transmittal Form	Drawing(s)	After Allowance Communication to Group				
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
After Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter				
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please identify below):				
Express Abandonment Request	Request for Refund	Form 1449, 4 pages (in duplicate) (79) References				
x Information Disclosure Statement, 3 pages	CD, Number of CD(s)	Return Postcard				
Certified Copy of Priority Document(s)						
Response to Missing Parts/	Remarks					
Incomplete Application	CUSTOMER NO. 25225					
Response to Missing Parts under 37 CFR 1.52 or 1.53	00010MER 140. 20223					
SIGNATI	JRE OF APPLICANT, ATTORNEY, OF	RAGENT				
Firm MORRISON & FOEl or James J. Mullen, III						
Signature						
Date April 15, 2004						
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.						

sd-194449

Dated: April 15, 2004



**CERTIFICATE OF MAILING BY "FIRST CLASS"** 

Phen Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Satyanarayana MEDICHERLA et al.

Serial No.:

10/728,665

Filing Date:

December 5, 2003

For:

METHODS FOR TREATING

**DIABETES** 

Examiner: Unassigned

Group Art Unit: 1614

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	re the mailing of a first Office Action after the filing of a Request for Continued
	Exam	nination under § 1.114.
$\boxtimes$	Withi	in three months of the application filing date or before mailing of a first Office
	Actio	on on the merits; accordingly, no fee or separate requirements are required.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
	<u> </u>	A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
	•	is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
	•	amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmitta
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 219002032800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 15, 2004

Respectfully submitted,

By:

Kames J. Mullen, III, Ph.D.

Reg. No. 44,957

Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500 San Diego, California 92130-2332

Telephone: (858) 720-7940 Facsimile: (858) 720-5125 Form PTO-1449.

# INFORMATION DISCE OSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 1 01 4
Docket Number 219002032800	Application Number 10/728,665
Applicant	

Satyanarayana MEDICHERLA et al.

Filing Date December 5, 2003 Group Art Unit 1614

Mailing Date April 15, 2004

### U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/1978	4,107,288	Oppenheim et al.	424	22	
	2.	10/1986	4,619,652	Eckenhoff et al.	604	415	
	3.	09/1992	5,145,684	Liversidge et al.	424	489	

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Transl YES	ation NO
	4.	07/1996	WO 96/21452 ·	PCT				
	5.	07/1996	WO 96/21654 ·	PCT				
	6.	12/1996	WO 96/40143 -	PCT				
	7.	07/1997	WO 97/25046 >	PCT				
	8.	10/1997	WO 97/35856 ·	PCT				
	9.	06/1998	WO 98/25619·	PCT				
	10.	12/1998	WO 98/56377 ·	PCT				
	11.	12/1998	WO 98/57966 ·	PCT				
	12.	07/1999	WO 99/32110 ·	PCT				
	13.	07/1999	WO 99/32121 ·	PCT				
	14.	07/1999	WO 99/32463 ·	PCT				
	15.	11/1999	WO 99/57101 .	PCT				
	16.	12/1999	WO 99/61440 ·	PCT				
	17.	12/1999	WO 99/64400 -	PCT	r			-
	18.	03/2000	WO 00/10563 .	PCT				
	19.	03/2000	WO 00/17204 .	PCT				
	20.	04/2000	WO 00/19824 ~	PCT				
	21.	07/2000	WO 00/41698 •	PCT				

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 .			Docket Number 2190020	32800	Application N	umber 10/728,	665		
<u> </u>			Applicant						
IN AN APPLICATION .			S	atyanarayana M	IEDICHERLA et	al.			
(Use several sheets if necessary)			Filing Date December 5.	2003	Group Art Un	it 1614			
	N			Mailing Date April 15,	2004				
	22.	11/2000	WO 00/64422 ·	PC	Γ				
	23.	11/2000	WO 00/71535 '	PC	Γ				
	24.	01/2001	WO 01/05749 ·	PC	Γ				
	25.	02/2001	WO 01/10865 .	PC	Γ				
	26.	05/2001	WO 01/38324 ·	PC	Γ				
	27.	09/2001	WO 01/64679 ·	PC	Γ				
	28.	09/2001	WO 01/66539 ·	PC	Γ				
	29.	09/2001	WO 01/66540 ·	PC	Γ		•		
	30.	01/2002	WO 02/07772 ·	PC	Γ				
			OTHE	R D	OCUMENTS	(includ	ing author, title, L	Date, Pertinent i	Pages, Etc.)
Examiner	Ref.	Title							
Initials	No.								
		Adams et al., Bioorg. Med. Chem. Lett. 8:3111-3116 (1998).							
	· 32.	Badger, J. Pl	harmacol. Exp. Ther.	279:	1453-1461 (1996).				
	、33.	Balasa et al.,	J. Immunology 165:	2841	-2849 (2000).				
	. 34.	Blair et al., J	J. Biol. Sci. 17:36293	-362	99 (1999).				
	<b>3</b> 5.	Burysek et a	l., J. Biol. Chem. 277	:335	09-33517 (2002).				
	' 36.	Casteels et a	l., Transplantation 65	5:122	5-1232 (1998).				
	• 37.		Diabetologia 44:325-						
-	, 38.	Cohen, "Dia Philadelphia	betes and Protein Gly, PA (1996).	ycatio	on" in: Clinical and	Pathophysic	ologic Releva	ance, JC Pro	ess,
	. 39.	Collis et al.,	Bioorg. Med. Chem.	Lett	. 11:693-696 (2001)	•			
	. 40	Crump, J. Fa	amily Practice 25:78-	82 (1	987).				
	· 41.	Debussche e	t al., Diabete & Meta	bolis	sme (Paris) 20:282-2	90 (1994).			
	· 42.	42. De Laszlo et al., Bioorg. Med. Chem. Lett. 8:2698 (1998).							
	. 43.	43 Fijen et al., Clin. Exp. Immunol. 124:16-20 (2001).							
	• 44.		al., Bioorg. Med. Ch						•
EXAMI	NER:				DATE CONS	IDERED:			
EXAMIN conforma	ER: Initia	al if citation cons ot considered. In	idered, whether or not the clude a copy of this form	citati with r	on conforms with MPEF next communication to a	P 609. Draw a pplicant.	line through th	e citation if no	ot in

Form PTO-1449		Docket Number 219002032800	Application Number 10/728,665		
INFORMATION DISCLOSURE CITATION		Applicant			
IN AN APPLICATION		Satyanarayana MEDICHERLA et al.			
(Use several sheets if necessary)		Filing Date December 5, 2003	Group Art Unit 1614		
i			Mailing Date April 15, 2004		
	, 45.	Goebeler et al., Blood 93:857-865 (199	99).		
	÷ 46.	Hale et al., J. Immunol. 162:4246-4252	2 (1999).		
	- 47.	Hancock et al., Am. J. Patho. 147:1194	4-1199 (1995).		
	48.	Harris, "Definition and Classification of 326-334, Table 32-3, in DIABETES MEds., 2 <sup>nd</sup> ed. (2000).	of Diabetes Mellitus and the Nev IELLITUS, A Fundamental and	w Criteria for Diagnosis," pp. Clinical Text, LeRoith D. et al.	
	· 49	Heinze and Thon, Pediatrician 12:208-	212 (1985).		
	. 50.	Herlaar and Brown, Molec. Med. Toda	ny 5:439-447 (1999).		
	, 51.	Hosker and Turner, Lancet 18:633-635	5 (1982).		
	. 52.	Jackson, J. Pharmacol. Exp. Ther. 284	:687-692 (1998).		
	- 53.	Keymeulen and Somer, Acta Clinica E	Belgica 48:86-95 (1993).		
	<b>^</b> 54.	Kimble et al., Endocrinol., 136:3054-3	061 (1995).		
	· 55.	Kumar et al., Biochem. Biophys. Res.	Comm. <b>235</b> :533-538 (1997).		
	. 56.	Lee et al., Immunopharmacology 47:1	85-201 (2000).		
	· 57.	Mahon et al., Ann. N.Y. Acad. Sci. 69	<b>6</b> :351-363 (1993).		
	, 58.	Makino et al., Exp. Animal 29:1-13 (1	980).		
	• 59.	McLay et al., Bioorg. Med. Chem. 9:5	37-554 (2001).		
	· 60.	Miyazaki et al. Clin. Exp. Immuno. 60	:622-630 (1985).		
	. 61.	Mori et al., Diabetologia 29:244-247 (	1986).		
	, 62.	Palmer and McCulloch, Diabetes 40:9	43-947 (1990).		
	. 63.	Pavlovic et al., Eur. Cytokine Netw. 1	1:267-274 (2000).		
	• 64.	Poste et al., Meth. Cell Biol. 14:33 (19	76).		
	, 65.	Rapoport et al., J. Exp. Med. 177:1221	-1227 (1993).		
	· 66.	Ravelli, Curr. Opin. Rheumatol. 14:54	8-552 (2002).		
	. 67.	Revesz et al., Bioorg. Med. Chem. Let	t., 10:1261-1264 (2000).		
	·68.	Rogers and Giembycz, Drug Discov.	Today 3:532-535 (1998).		
	, 69.	Ryu et al., J. Clin. Invest. 108:63-72 (2	2001).		
	<b>,</b> 70.	Salomon et al., Immunity 12:431-437	(2000).		
	. 71.	Shapiro et al., Diabetologia 45:224-23	0 (2002).		
	. 72.	Sprinkel et al., Eur. Cytokine Netw. 12			
	· 73.	Sugihara et al., Histol. Histopathol. 4:	397-404 (1989).		
EXAMIN	ER:		DATE CONSIDERED:		
EXAMINI conforman	ER: Initia	al if citation considered, whether or not the citation considered. Include a copy of this form with n	on conforms with MPEP 609. Draw a lext communication to applicant.	ine through the citation if not in	

PTO/SB/ 08 (2-92) sd- 178364 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 - ·	Docket Number 219002032800 Application Number 10/728,665			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Satyanarayana MEDICHERLA et al.			
(Use several sheets if necessary)	Filing Date December 5, 2003 Group Art Unit 1614			
	Mailing Date April 15, 2004			
. 74 Tabatabaie et al., Biochem. Biophys.	Res. Comm. 273:699-704 (2000).			
· 75. Thomas and Kay, Diabetes/Metabolis				
, 76. Wadsworth et al., J. Pharmacol. Expt.	Therapeut. <b>291</b> :680-687 (1999).			
、77 Wang, Structure 6:1117-1128 (1998).				
. 78 Yoshida and Kikutani, Reviews in Im				
· 79 Zhang et al., International Immunolog	gy <b>13</b> :377-384 (2001).			
	·			
EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the cita conformance and not considered. Include a copy of this form with	tion conforms with MPEP 609. Draw a line through the citation if not in			